行情

CYCN

CYCN

Cyclerion Therapeutics Inc
NASDAQ

实时行情|Nasdaq Last Sale

11.14
+0.04
+0.36%
盘后: 11.14 0 0.00% 16:00 09/13 EDT
开盘
11.26
昨收
11.10
最高
11.87
最低
11.14
成交量
8.73万
成交额
--
52周最高
22.85
52周最低
7.83
市值
3.05亿
市盈率(TTM)
-2.3511
分时
5日
1月
3月
1年
5年

分析师评级

1位分析师的综合评级

中性

免责声明:分析师观点仅供投资者决策参考,不构成任何买卖投资建议。

EPS

CYCN 新闻

  • 沙特抢修石油设施 预计沙特阿美几周内恢复全部产能
  • 新浪美股.2小时前
  • iPhone 11预售首个周末遭疯抢 缺席5G恐影响短期销量
  • 第一财经.4小时前
  • 沙特阿美遇袭 油价会飙升吗?
  • 新浪财经综合.5小时前
  • 新华社:无人机袭击致沙特石油减产一半
  • 新华社.5小时前

更多

所属板块

生物技术和医学研究
+0.20%
制药与医学研究
-0.38%

热门股票

名称
价格
涨跌幅

CYCN 简况

Cyclerion Therapeutics, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on discovering, developing and commercializing treatments for serious and orphan diseases. The Company develops guanylate cyclase (sGC) stimulators. The Company’s portfolio includes five sGC stimulator programs: olinciguat, praliciguat, IW-6463 and two organ-targeted programs. Olinciguat is an oral, once-daily vascular sGC stimulator for patients suffering from sickle cell disease. Olinciguat is in Phase II trial. Praliciguat is an oral, once-daily systemic sGC stimulator for heart failure with preserved ejection fraction (HFpEF) and for diabetic nephropathy. Praliciguat is in two separate Phase II trials. IW-6463 is a central nervous system-penetrant oral sGC stimulator. IW-6463 is in a Phase I and is designed to treat serious and orphan neurodegenerative diseases. Its two organ-targeted programs are designed to address serious and orphan diseases of the liver and lung.
展开

Webull提供Cyclerion Therapeutics Inc的股票价格,实时市场报价,专业分析师评级,深度图表和免费的股票新闻,以帮助您做出投资决策。